AIKI vs. XELB, BIAF, PLAG, MTEX, ORGS, PIRS, AYTU, MHUA, AVTX, and DOMH
Should you be buying AIkido Pharma stock or one of its competitors? The main competitors of AIkido Pharma include Xcel Brands (XELB), bioAffinity Technologies (BIAF), Planet Green (PLAG), Mannatech (MTEX), Orgenesis (ORGS), Pieris Pharmaceuticals (PIRS), Aytu BioPharma (AYTU), Meihua International Medical Technologies (MHUA), Avalo Therapeutics (AVTX), and Dominari (DOMH).
AIkido Pharma (NASDAQ:AIKI) and Xcel Brands (NASDAQ:XELB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Xcel Brands received 133 more outperform votes than AIkido Pharma when rated by MarketBeat users. However, 63.92% of users gave AIkido Pharma an outperform vote while only 50.21% of users gave Xcel Brands an outperform vote.
AIkido Pharma has higher earnings, but lower revenue than Xcel Brands. AIkido Pharma is trading at a lower price-to-earnings ratio than Xcel Brands, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xcel Brands had 18 more articles in the media than AIkido Pharma. MarketBeat recorded 18 mentions for Xcel Brands and 0 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.67 beat Xcel Brands' score of 0.02 indicating that AIkido Pharma is being referred to more favorably in the media.
AIkido Pharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Xcel Brands has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 18.6% of Xcel Brands shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 52.4% of Xcel Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
AIkido Pharma has a net margin of 0.00% compared to Xcel Brands' net margin of -118.57%. AIkido Pharma's return on equity of -18.21% beat Xcel Brands' return on equity.
Summary
Xcel Brands beats AIkido Pharma on 9 of the 15 factors compared between the two stocks.
Get AIkido Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIkido Pharma Competitors List
Related Companies and Tools
